La cadena de opciones muestra datos clave de las opciones de acciones de NeuroBo Pharmaceuticals a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para NeuroBo Pharmaceuticals..

NeuroBo Pharmaceuticals (NASDAQ:NRBO) Bolsa, Cadena de Opciones

NeuroBo Pharmaceuticals

NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.

NeuroBo Pharmaceuticals, Inc. - Common Stock

NeuroBo Pharmaceuticals Inc

Maxim Group analyst Jason McCarthy maintained a Buy rating on NeuroBo Pharmaceuticals (NRBO – Research Report) yesterday and set a price target of ...

Buy Rating on NeuroBo Pharmaceuticals: Strategic Alliances and Market Differentiation Potential

NeuroBo Pharmaceuticals (NRBO) has issued an update. NeuroBo Pharmaceuticals, Inc. has successfully completed the enrollment for the first part of ...

NeuroBo Completes First Phase 1 Enrollment for Obesity Drug Trial

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>NeuroBo Pharmaceuticals</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/nrbo-stock-quote/"><strong>NRBO</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>NeuroBo Pharmaceuticals reported earnings per share of -$1.85. This was below the analyst estimate for EPS of -$1.12.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/nrbo-stock-earnings-neurobo-pharmaceuticals-for-q2-of-2024/">NRBO Stock Earnings: NeuroBo Pharmaceuticals Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

NRBO Stock Earnings: NeuroBo Pharmaceuticals Misses EPS for Q2 2024

Jason McCarthy, an analyst from Maxim Group, reiterated the Buy rating on NeuroBo Pharmaceuticals (NRBO – Research Report). The associated price ta...

Buy Rating for NeuroBo Pharmaceuticals Based on Financial Stability and Promising Developmental Pipeline

NeuroBo Pharmaceuticals GAAP EPS of -$1.85

NeuroBo Pharmaceuticals ( ($NRBO) ) just unveiled an update. NeuroBo Pharmaceuticals, Inc. has announced promising results from Part 1 of the Phase...

NeuroBo's DA-1726 Shows Promise in Obesity Trial Phase 1

An announcement from NeuroBo Pharmaceuticals ( ($NRBO) ) is now available. NeuroBo Pharmaceuticals, Inc. has updated its corporate presentation on ...

NeuroBo Pharmaceuticals Unveils Updated Corporate Presentation

Catalyst Watch: Netflix earnings, Lenovo tech event, Paris Motor Show, and eyes on oil

NeuroBo Pharmaceuticals GAAP EPS of -$0.55 beats by $0.18

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on NeuroBo Pharmaceuticals (NRBO – Research Report). The associated price ta...

NeuroBo Pharmaceuticals: Promising MASH and Obesity Treatment Pipeline Driving Buy Rating

ADBE

ALLY

BLNK

BYDDF

CAPR

CTRI

CYTK

IBTA

INTC

LNVGY

MIRM

MSFT

MTEN

NAPA

NFLX

NRBO

NVDA

NVNO

OCGN

OKTA

QCOM

SCHW

SERV

SFHG

SRRK

TSLA

ULTA

USGO

VANI

VLKAF

VRSSF

Press Releases

NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01

NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Earnings

NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update

NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals to Participate in Investor Conferences in October

NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Comments

NeuroBo Pharmaceuticals

NeuroBo Pharmaceuticals (NRBO) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL